HypertensionRandomised controlled trial
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
- Randomised controlled trial
- phase 1
- single ascending dose
- placebo-controlled
Authors' conclusion
Dose-dependent decreases in serum angiotensinogen levels and 24-hour ambulatory blood pressure were sustained for up to 24 weeks after a single subcutaneous dose of zilebesiran of 200 mg or more; mild injection-site reactions were observed.
Study context
- Population
- Patients with hypertension
- Participants
- 107 patients
- Comparison
- Zilebesiran vs placebo
Primary result
As reported in the abstract
Dose correlation of serum angiotensinogen decrease (r)
−0.56 (95% CI −0.69 to −0.39)
Doses ≥200 mg: SBP decrease (mm Hg) by week 8, sustained at 24 weeks
>10
Doses ≥200 mg: DBP decrease (mm Hg) by week 8, sustained at 24 weeks
>5
Further findings
BP effect with high-salt diet (Part B) and with irbesartan (Part E)
- Attenuated by high-salt diet; augmented by coadministration with irbesartan
Safety
Mild, transient injection-site reactions
- Patients with injection-site reactions
- 5
Hypotension, hyperkalemia, or worsening renal function resulting in medical intervention
- No reports
Original publication
Summarised from the published abstract; every number is checked against it